DS 5141b

Drug Profile

DS 5141b

Alternative Names: DS-5141; DS-5141b

Latest Information Update: 25 Apr 2017

Price : $50

At a glance

  • Originator Daiichi Sankyo Inc
  • Class
  • Mechanism of Action Dystrophin expression stimulants; Protein synthesis modulators; RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Duchenne muscular dystrophy

Most Recent Events

  • 24 Apr 2017 The Ministry of Health, Labour and Welfare designates SAKIGAKE designation dystem to DS 5141b for Duchenne muscular dystrophy in Japan
  • 01 Oct 2015 Phase-I/II clinical trials in Duchenne muscular dystrophy in Japan (SC) (NCT02667483)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top